AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24942311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23688777 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isokinetic eccentric exercise (EE) muscle damage protocol (5×15) of the knee extensors and flexors at 60°/s
Number of subjects: 15
Study 23688777 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled walking speed during COND2 (±5% of pre-EE speed)
Number of subjects: 15
Study 21308360 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (130/0.4)
Number of subjects: 7000
Study 21308360 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline)
Number of subjects: 7000
Study 19614965 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (150 mg)
Number of subjects: 15
Study 19614965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18001616 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 0
Study 14688699 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg twice daily (n = 21)
Number of subjects: 64
Study 14688699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin (n = 20)
Number of subjects: 64
Study 14688699 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 64
Study 14688699 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 64
Study 14635283 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dance-based exercise program (8 weeks)
Number of subjects: 10
Study 14635283 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotion biomechanical analysis
Number of subjects: 10
Study 14635283 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute gait test
Number of subjects: 10
Study 14635283 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-foot gait test
Number of subjects: 10
Study 8825016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocuguard (broad spectrum antioxidant capsule)
Number of subjects: 84
Study 8825016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 1373372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 5
Study 1373372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 5
Study 1373372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3900361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 60
Study 3900361 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 60
Study 3900361 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 60
Study 3900361 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 60
Study 3696105 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxyhemoglobin levels of 16-23%
Number of subjects: 18
Study 3696105 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 23)
Number of subjects: 18
Study 29505553 — intervention group
Group type: EXPERIMENTAL
Intervention: Steato‐ELSA
Number of subjects: 9857
Study 29505553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty Liver Index
Number of subjects: 9857
Study 29505553 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic Steatosis Index
Number of subjects: 9857
Study 29505553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic Fatty Liver Disease‐Liver Fat Score
Number of subjects: 9857
Study 29558987 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher scheme to promote physical activity
Number of subjects: 78
Study 28566688 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose HDM specific sublingual immunotherapy (n = 29)
Number of subjects: 77
Study 28566688 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose HDM specific sublingual immunotherapy (n = 26)
Number of subjects: 77
Study 28566688 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 77
Study 26187555 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-based therapy for 12 weeks
Number of subjects: 1441
Study 24107662 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane 4‐6% (Group D)
Number of subjects: 56
Study 24107662 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane 1‐2% (Group S)
Number of subjects: 56
Study 20604775 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC) in NETHCON
Number of subjects: 139218
Study 20604775 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology (CC) in NETHCON
Number of subjects: 139218
Study 20604775 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC) in NTCC
Number of subjects: 139218
Study 20604775 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology (CC) in NTCC
Number of subjects: 139218
Study 18472200 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-education programs targeting both couple relationship and parenting
Number of subjects: 0
Study 18472200 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education programs targeting couple relationship
Number of subjects: 0
Study 18472200 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education programs targeting parenting
Number of subjects: 0
Study 16700881 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day)
Number of subjects: 30
Study 16700881 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (20 mg/day)
Number of subjects: 30
Study 16700881 — intervention group
Group type: COMPARATOR
Intervention: ACEI (imidapril 5 mg/day)
Number of subjects: 30
Study 16700881 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI (imidapril 5 mg/day) + Spironolactone (25 mg/day)
Number of subjects: 30
Study 16700881 — intervention group
Group type: COMPARATOR
Intervention: ACEI (imidapril 5 mg/day) + Furosemide (20 mg/day)
Number of subjects: 30
Study 12699450 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (Genotropin, 0.8 IU daily for 1 month, then 1.6 IU daily for 5 months)
Number of subjects: 19
Study 12699450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10781127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal intubation in glaucomatous children
Number of subjects: 35
Study 10781127 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation in normal children
Number of subjects: 35
Study 10781127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal extubation in glaucomatous children
Number of subjects: 35
Study 10781127 — intervention group
Group type: COMPARATOR
Intervention: Tracheal extubation in normal children
Number of subjects: 35
Study 8638600 — intervention group
Group type: EXPERIMENTAL
Intervention: Burstone‐type intrusion arch delivering low level of force (about 15 gm per tooth)
Number of subjects: 17
Study 8638600 — intervention group
Group type: COMPARATOR
Intervention: Full‐arch fixed appliances (control group)
Number of subjects: 17
Study 1465036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (sCT) 200 IU/day, continuous regimen for 2 years
Number of subjects: 48
Study 1465036 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin (sCT) 200 IU/day, cyclic regimen (3 months on, 1 month off) for 2 years
Number of subjects: 48
Study 1465036 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation alone (500 mg/day)
Number of subjects: 48
Study 6146570 — intervention group
Group type: COMPARATOR
Intervention: 6-month exercise training programme (5BX/XBX)
Number of subjects: 17
Study 6146570 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance training (up to 4.5 years)
Number of subjects: 17
Study 6146570 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance training in patients on beta-blocker therapy
Number of subjects: 17
Study 29589419 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexed neck position
Number of subjects: 39
Study 29589419 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended neck position
Number of subjects: 39
Study 29589419 — intervention group
Group type: COMPARATOR
Intervention: Neutral position
Number of subjects: 39
Study 29589419 — intervention group
Group type: EXPERIMENTAL
Intervention: Right rotated head and neck position
Number of subjects: 39
Study 29176359 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual intravenous simulator
Number of subjects: 65
Study 29176359 — intervention group
Group type: COMPARATOR
Intervention: Plastic arm model
Number of subjects: 65
Study 29176359 — intervention group
Group type: COMPARATOR
Intervention: Control group symptoms
Number of subjects: 65
Study 26669692 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized working memory training (CWMT)
Number of subjects: 66
Study 26669692 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 66
Study 25304939 — intervention group
Group type: EXPERIMENTAL
Intervention: Practicing two procedures (an appendectomy followed by a salpingectomy)
Number of subjects: 96
Study 25304939 — intervention group
Group type: COMPARATOR
Intervention: Practicing only one procedure (a salpingectomy)
Number of subjects: 96
Study 22067902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg oral monthly
Number of subjects: 70
Study 22067902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 20499222 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging for lumbar spinous process identification
Number of subjects: 74
Study 18497717 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy for Substance Abusers (DBT-SAB)
Number of subjects: 0
Study 15891919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber rate-modulated pacing
Number of subjects: 23
Study 15891919 — intervention group
Group type: COMPARATOR
Intervention: Ventricular pacing
Number of subjects: 23
Study 11792604 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate (doses: 0.25, 0.50, 1.0, 2.5, or 5.0 mg daily)
Number of subjects: 180
Study 11792604 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate
Number of subjects: 180
Study 11012955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation protocol with rectal midazolam (0.5 mg x kg(‐1)) and S‐(+)‐ketamine (5 mg x kg(‐1)) plus i.v. supplementation (20+/‐10 microg x kg(‐1) x min(‐1) S‐(+)‐ketamine and 4+/‐2 microg x kg(‐1) x min(‐1) midazolam)
Number of subjects: 34
Study 11012955 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 34
Study 8787886 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg genaconazole (racemate)
Number of subjects: 12
Study 8787886 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg or 200 mg genaconazole (RR enantiomer)
Number of subjects: 12
Study 8787886 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of 14C-labeled genaconazole
Number of subjects: 12
Study 1449110 — intervention group
Group type: EXPERIMENTAL
Intervention: 2'-deoxycoformycin (dCF) alone
Number of subjects: 49
Study 1449110 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2'-deoxycoformycin (dCF) and adenine arabinoside (ara-A)
Number of subjects: 49
Study 4016828 — intervention group
Group type: EXPERIMENTAL
Intervention: Wax-matrix iron preparation
Number of subjects: 181
Study 4016828 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release iron preparation
Number of subjects: 181
Study 31066079 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel matching algorithms
Number of subjects: 0
Study 31066079 — intervention group
Group type: COMPARATOR
Intervention: Current matching algorithms
Number of subjects: 0
Study 29027815 — intervention group
Group type: EXPERIMENTAL
Intervention: l‐carnosine (800 mg/day in 2 divided doses)
Number of subjects: 70
Study 29027815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 27411697 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of type 2 diabetes
Number of subjects: 542
Study 27411697 — intervention group
Group type: COMPARATOR
Intervention: Before development of type 2 diabetes
Number of subjects: 542
Study 27411697 — intervention group
Group type: EXPERIMENTAL
Intervention: After development of type 2 diabetes
Number of subjects: 542
Study 27411697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative mortality in participants who developed type 2 diabetes in first 10 years
Number of subjects: 542
Study 27411697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative mortality in participants who progressed to type 2 diabetes in 10-20 years
Number of subjects: 542
Study 27411697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative mortality in those who did not develop type 2 diabetes within 20 years
Number of subjects: 542
Study 23379386 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong African American Families‐Teen (SAAF‐T) program
Number of subjects: 502
Study 23379386 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 502
Study 23379386 — intervention group
Group type: COMPARATOR
Intervention: SAAF‐T and Control condition
Number of subjects: 502
Study 23924044 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte count and CRP in the lowest tertile
Number of subjects: 888
Study 23924044 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte count and VCAM-1 in the lowest tertile
Number of subjects: 888
Study 20535926 — intervention group
Group type: EXPERIMENTAL
Intervention: Simiao Xiaobi Decoction (SXD)
Number of subjects: 120
Study 20535926 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 120
Study 18160247 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oxaliplatin (Ox)
Number of subjects: 173
Study 18160247 — intervention group
Group type: EXPERIMENTAL
Intervention: Other chemotherapeutic agents (OC)
Number of subjects: 173
Study 18160247 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (SA)
Number of subjects: 173
Study 15850123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic analysis
Number of subjects: 43
Study 15850123 — intervention group
Group type: COMPARATOR
Intervention: Static analysis
Number of subjects: 43
Study 15850123 — intervention group
Group type: EXPERIMENTAL
Intervention: Static and dynamic models
Number of subjects: 43
Study 14628178 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate (10 mg, injected every second week for 24 weeks)
Number of subjects: 281
Study 14628178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (injected every second week for 24 weeks)
Number of subjects: 281
Study 14628178 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate (10 mg) in male patients
Number of subjects: 281
Study 14628178 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupenthixol decanoate (10 mg) in female patients
Number of subjects: 281
Study 10511763 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate stabilization with simple external fixation (group 2, 72 patients)
Number of subjects: 112
Study 10511763 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (group 1, 40 patients)
Number of subjects: 112
Study 7670929 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha (2 x 10(6) IU/g)
Number of subjects: 60
Study 7670929 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllotoxin 0.5% in hydrophilic cream
Number of subjects: 60
Study 7670929 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60
Study 2189027 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Hydrochlorothiazide + Methyldopa
Number of subjects: 120
Study 2189027 — intervention group
Group type: COMPARATOR
Intervention: Standard Triple Therapy (Hydrochlorothiazide + Propranolol + Hydralazine)
Number of subjects: 120
Study 7005629 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (2.5 mg/kg orally on two consecutive days each week for 26 weeks)
Number of subjects: 33
Study 7005629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7005629 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 33
Study 31082942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy in combination with sunitinib
Number of subjects: 0
Study 31082942 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib alone
Number of subjects: 0
Study 28486723 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with the WaveLight Refractive Suite
Number of subjects: 96
Study 26134359 — intervention group
Group type: EXPERIMENTAL
Intervention: (1→3)‐β‐d‐glucan (BDG) assay with cutoff positivity ≥80 pg/mL
Number of subjects: 107
Study 26134359 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida albicans germ tube antibody (CAGTA) assay with cutoff positivity ≥1/160
Number of subjects: 107
Study 26134359 — intervention group
Group type: EXPERIMENTAL
Intervention: BDG and CAGTA kinetics in IC patients treated with antifungals
Number of subjects: 107
Study 26134359 — intervention group
Group type: COMPARATOR
Intervention: Confounding factors (amoxicillin–clavulanate, piperacillin–tazobactam treatments, recent surgery, Gram‐positive bloodstream infection, renal replacement therapy, enteral nutrition)
Number of subjects: 107
Study 23660324 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-direct thrombolysis (group B)
Number of subjects: 86
Study 23660324 — intervention group
Group type: COMPARATOR
Intervention: Peripheral venous thrombolysis (group A)
Number of subjects: 86
Study 23660324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 86
Study 21824041 — intervention group
Group type: EXPERIMENTAL
Intervention: Dash® device with a display fixed on the cutting blocks
Number of subjects: 30
Study 21824041 — intervention group
Group type: COMPARATOR
Intervention: Kolibri® device with an external display
Number of subjects: 30
Study 19470696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib 600 mg orally twice a day for the first 21 consecutive days in 28-day cycles
Number of subjects: 457
Study 19470696 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC), including hydroxyurea
Number of subjects: 457
Study 17291792 — intervention group
Group type: EXPERIMENTAL
Intervention: VR iliac training module (group A)
Number of subjects: 20
Study 17291792 — intervention group
Group type: EXPERIMENTAL
Intervention: VR renal training module (group B)
Number of subjects: 20
Study 17291792 — intervention group
Group type: COMPARATOR
Intervention: Crossover performance of group B (renal trained) on simulated iliac task
Number of subjects: 20
Study 17291792 — intervention group
Group type: COMPARATOR
Intervention: Crossover performance of group A (iliac trained) on simulated renal task
Number of subjects: 20
Study 15209646 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg four times a day (qid)
Number of subjects: 39
Study 15209646 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered qid with acetaminophen as needed (prn)
Number of subjects: 39
Study 11207351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (body temperature, 33 degrees C)
Number of subjects: 392
Study 11207351 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 392
Study 11207351 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 392
Study 9625044 — intervention group
Group type: EXPERIMENTAL
Intervention: %CDT TIA
Number of subjects: 204
Study 9625044 — intervention group
Group type: EXPERIMENTAL
Intervention: CDTect
Number of subjects: 204
Study 8120721 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal CPAP until resolution of lung disease
Number of subjects: 124
Study 8120721 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 hours of nasopharyngeal CPAP
Number of subjects: 124
Study 8120721 — intervention group
Group type: COMPARATOR
Intervention: Oxygen supplementation delivered by hood
Number of subjects: 124
Study 2535953 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation plus ACNU (30 mg/m2 x 4 times during irradiation)
Number of subjects: 77
Study 2535953 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (50 to 60 Gy/5 to 6 weeks)
Number of subjects: 77
Study 2535953 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation plus ACNU
Number of subjects: 77
Study 2535953 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 77
Study 792861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin ('Bolvidon') at an average dose of 40 mg a day
Number of subjects: 0
Study 792861 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine at an average dose of 100 mg a day
Number of subjects: 0
Study 792861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 792861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 792861 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 792861 — intervention group
Group type: COMPARATOR
Intervention: Mianserin, Imipramine, and Placebo
Number of subjects: 0
Study 31488314 — intervention group
Group type: EXPERIMENTAL
Intervention: Roluperidone 32 mg
Number of subjects: 244
Study 31488314 — intervention group
Group type: EXPERIMENTAL
Intervention: Roluperidone 64 mg
Number of subjects: 244
Study 31488314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 30886125 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nemiralisib (0.1‐6.4 mg) for up to 14 days
Number of subjects: 56
Study 30886125 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nemiralisib (2 mg, once daily)
Number of subjects: 56
Study 30886125 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nemiralisib
Number of subjects: 56
Study 28926159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine (1 mg/kg)
Number of subjects: 87
Study 28926159 — intervention group
Group type: COMPARATOR
Intervention: Intranasal Fentanyl (1.5 μg/kg)
Number of subjects: 87
Study 25913538 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (24-week double blind trial)
Number of subjects: 1152
Study 25913538 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24-week double blind trial)
Number of subjects: 1152
Study 25913538 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment as usual
Number of subjects: 1152